- Home
- OSW vs NAMS Comparison
OSW vs NAMS Comparison
Compare OSW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSW | NAMS |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | Bahamas | Netherlands |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OSW | NAMS |
|---|---|---|
| Price | $23.78 | $19.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $31.20 | ★ $49.80 |
| AVG Volume (30 Days) | 612.5K | ★ 1.2M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $961,001,000.00 | $22,503,000.00 |
| Revenue This Year | $7.61 | $30.15 |
| Revenue Next Year | $8.69 | $384.12 |
| P/E Ratio | $55.16 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $19.06 | $19.58 |
| 52 Week High | $29.25 | $42.21 |
Technical Indicators
Market Signals| Indicator | OSW | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 36.15 |
| Support Level | $23.14 | $19.58 |
| Resistance Level | $24.96 | $37.30 |
| Average True Range (ATR) | 0.55 | 1.17 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 51.01 | 16.58 |
Price Performance
Historical ComparisonAbout OSW OneSpaWorld Holdings Limited
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.